INVO Bioscience, Inc. Stock

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-22 pm EDT 5-day change 1st Jan Change
0.9139 USD -0.04% Intraday chart for INVO Bioscience, Inc. -14.59% -32.30%
Sales 2022 822K Sales 2023 3.02M Capitalization 3.34M
Net income 2022 -10M Net income 2023 -8M EV / Sales 2022 9.4 x
Net Debt 2022 2.57M Net Debt 2023 8.45M EV / Sales 2023 3.9 x
P/E ratio 2022
-0.47 x
P/E ratio 2023
-0.26 x
Employees 28
Yield 2022 *
-
Yield 2023
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.04%
1 week-14.59%
Current month-8.61%
1 month-26.30%
3 months-0.66%
6 months-50.60%
Current year-32.30%
More quotes
1 week
0.89
Extreme 0.89
1.12
1 month
0.85
Extreme 0.85
1.28
Current year
0.70
Extreme 0.7
3.50
1 year
0.50
Extreme 0.5
8.60
3 years
0.50
Extreme 0.5
108.55
5 years
0.50
Extreme 0.5
273.54
10 years
0.50
Extreme 0.5
953.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-10-10
Director of Finance/CFO 56 21-06-13
Chief Tech/Sci/R&D Officer - 20-11-30
Members of the board TitleAgeSince
Director/Board Member 56 19-12-15
Director/Board Member 64 20-09-13
Corporate Secretary 55 08-09-30
More insiders
Date Price Change Volume
24-05-22 0.9139 -0.04% 127,945
24-05-21 0.9143 -1.58% 89,645
24-05-20 0.929 -5.69% 106,478
24-05-17 0.985 -1.50% 97,640
24-05-16 1 -6.54% 514,009

Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT

More quotes
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
More about the company